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Abstract Purpose:This study aimed to define themaximum tolerated dose of weekly docetaxel combined
with daily erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor.
Experimental Design: Patients with any solid tumor received150 mg erlotinib with escalating
doses of docetaxel (20, 25, 30, and 35mg/m2) ondays1, 8, and15 every 28 days.Thepharmaco-
kinetics of docetaxel and erlotinib was determined on cycle 2, day 1. Erlotinib was given for a
maximumof12 cycles anddocetaxelwas given for up to 6 cycles.
Results: Twenty-five patients (17 males and 8 females) were enrolled with a median age of
56 years (range, 34-76); Eastern Cooperative Oncology Group performance status of 0/1was
20/5. One patient had a dose-limiting toxicity in cycle1at the 25 mg/m2 level (grade 3 enteroco-
litis). At 35 mg/m2 docetaxel dose level, 6 of 10 patients required dose reductions to 30 mg/m2
beyond cycle1due to neutropenia (3 patients) and mucositis, increased bilirubin, and diarrhea (1
patient each). The clearance of docetaxel and erlotinib of 61.7 and 8.16 L/h, respectively, did not
seem to differ from historical controls. Responses were seen in non ^ small cell lung cancer,
prostate cancer, and hepatobiliary cancers, including a complete response lasting 36+ months
in a patient with hepatocellular carcinoma.
Conclusion: Although no maximum tolerated dose was reached in cycle 1with 35 mg/m2
docetaxel, repetitive dosing proved intolerable in a substantial number of patients; thus, the
recommended phase II dose of weekly docetaxel is 30 mg/m2 when combined with 150 mg of
daily erlotinib.
The epidermal growth factor receptor (EGFR) is overexpressed
and associated with a poor prognosis in many cancers (1–8).
Several lines of evidence support the deleterious effects
associated with EGFR overexpression, both via activation of
the Ras-mitogen-activated protein kinase–mediated cell prolif-
eration (9), inhibition of apoptosis via phosphatidylinositol
3-kinase-Akt and mammalian target of rapamycin pathway (9),
as well as promoting cell survival by inducing vascular
endothelial growth factor expression and angiogenesis (10, 11).
Erlotinib (Tarceva, OSI-774; OSI Pharmaceuticals) is an
orally active reversible inhibitor of the EGFR tyrosine kinase
enzyme that blocks cell cycle progression in the G1 phase.
Erlotinib inhibits the tyrosine kinase activity with an IC50 of
2 nmol/L and decreases EGFR autophosphorylation in intact
tumor cells with an IC50 of 20 nmol/L. Erlotinib confers a
survival advantage and is approved for clinical use in the
United States as a single agent in non–small cell lung cancer
(12) and in combination with gemcitabine for pancreatic
cancer (13). Taxanes are cytotoxic agents that bind to tubulin
and prevent microtubule disassembly. Docetaxel has also been
found to inhibit angiogenesis and induce apoptosis in both
in vitro and in vivo models, and most importantly, it has been
shown to have clinical activity in numerous tumor types
(14–17). Preclinical data showed that EGFR inhibition in
combination with docetaxel conferred increased antiprolifer-
ative and cytotoxic effects in various cancer cell lines and tumor
models (18–20). Prior phase I studies tested docetaxel
administered every 3 weeks with erlotinib and showed no
significant pharmacokinetic interactions but an inability to give
full doses of both drugs. Recommended phase II doses were 60
to 70 mg/m2 docetaxel every 3 weeks and 100 mg erlotinib
orally daily (21) or 200 mg erlotinib on days 2 to 16 every
3 weeks (22).
In this study, we aimed to define the maximum tolerated
dose (MTD) of weekly docetaxel in combination with erlotinib
and to analyze the pharmacokinetics, safety, and tolerability of
this regimen in patients with taxane-naive malignancies. The
pharmacokinetics of docetaxel and erlotinib was done after
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28 days of continuous erlotinib dosing, when the latter was at
steady state. The pharmacokinetic data were to be compared
with historical controls.
Materials andMethods
Patients with advanced solid tumors were eligible if they received no
more than one previous chemotherapy regimen for metastatic disease,
had an Eastern Cooperative Oncology Group performance status V2,
and had adequate hematopoietic function [aspartate aminotransferase/
alanine aminotransferase V1.5 upper limit of normal (ULN) if
alkaline phosphatase V ULN or alkaline phosphatase V4 ULN if
aspartate aminotransferase/alanine aminotransferase V ULN, bilirubin
V ULN and creatinine V1.5 ULN or creatinine clearance >60 mL/min/
m2]. Patients were excluded from the study if they had chemotherapy
within 4 weeks, radiation therapy within 2 weeks, symptomatic brain
metastases or requiring corticosteroids, or prior taxane exposure except
adjuvant taxanes completed more than 12 months before. All
participating patients signed an informed consent form reviewed and
approved by the Indiana University Review Board.
Study design. This was a single-center, phase I, dose-escalation study
to establish the MTD of weekly docetaxel combined with daily
erlotinib. Erlotinib (150 mg) was taken orally daily. Docetaxel was
given on days 1, 8, and 15 of each 28-day cycle and infused over
30 min. Premedication for weekly docetaxel consisted of 4 mg
dexamethasone orally for three doses beginning the day before,
morning of, and the day after docetaxel infusion. Docetaxel doses
started at 20 mg/m2 and escalated to 25, 30, and 35 mg/m2 in cohorts
of three patients per level. A standard ‘‘3 + 3’’ design was used. If one of
three patients experienced dose-limiting toxicity (DLT), an additional
three patients were accrued to that dose level. If two or more patients in
a cohort experienced DLT, then the previous dose was considered the
MTD and dose escalation was terminated. Additional 7 patients were
entered to ensure 10 patients were treated at the MTD. Patients were to
be treated for up to 6 cycles of docetaxel and 12 cycles of erlotinib. The
pharmacokinetic profiles of docetaxel and erlotinib were defined on
cycle 2, day 1.
Definition of DLT and dose modifications. DLT was defined as any of
the following events during the first cycle: grade 4 thrombocytopenia,
grade 4 neutropenia lasting more than 7 days, grade 3 or 4 febrile
neutropenia, any grade 3/4 nonhematologic toxicity related to the
combination therapy except nausea/vomiting or alopecia, or missing
two doses of docetaxel per dosing guidelines due to failure to recover
hematologic counts. Dose reductions were based on hematologic and
nonhematologic toxicities. No more than two dose modifications were
allowed for any one patient. Treatment was discontinued for disease
progression, unacceptable toxicity, therapy delay for more than 3 weeks
because of any toxicity, and withdrawal of consent. All patients who
received at least one dose of docetaxel and erlotinib were evaluable for
safety. Response to therapy was assessed by using the Response
Evaluation Criteria in Solid Tumors criteria (23).
Pharmacokinetics. Plasma samples for pharmacokinetic analysis
were obtained on cycle 2, day 1 for docetaxel and erlotinib (OSI-774)
and its metabolite, OSI-420. Erlotinib and docetaxel administrations
were started at the same time and pharmacokinetic samples were
collected before treatment, at the end of the docetaxel infusion, and
then 15 min, 45 min, 2 h, 3 h, 6.5 h, 8 h, and 24 h after the end of the
docetaxel infusion. Erlotinib and its O-demethylated metabolite, OSI-
420, concentrations were extracted from plasma under basic conditions
with hexane/ethyl acetate (50:50). Then, erlotinib and OSI-420 were
quantified by liquid chromatography-tandem mass spectrometry using
midazolam as the internal standard (24). The standard curve concen-
trations ranged from 10 to 5,000 ng/mL. The pharmacokinetics of
erlotinib concentrations was done using noncompartmental methods
with WinNonlin version 5.01. Docetaxel concentrations were deter-
mined using a validated liquid chromatography-mass spectrometry
assay in atmospheric pressure chemical ionization mode. The assay was
linear from 1 to 1,000 ng/mL using 1 mL plasma. The coefficient of
variation for the low control (75 ng/mL) and the high control
(500 ng/mL) was <10%. The assay was done as previously reported,
with the exception that paclitaxel was used as the internal standard and
docetaxel was the analyte of interest (25). ADAPT II software was used
for docetaxel pharmacokinetic data analysis (Biomedical Simulations
Resource; ref. 26). A three-compartment model was fit to each patient
data using a Bayesian algorithm as implemented in ADAPT II software.
Prior variable distributions were derived from the literature (27).
Statistical analysis. Acceptable toxicity of this regimen was consid-
ered if none of three patients, or less than one or one of six patients had
DLT. Based on the binomial distribution for toxicity occurrence, there
was at most a 17% chance of escalating to the next dose level when the
true toxicity rate exceeded 50%. With six patients in a cohort, there was
at least a 74% chance of observing any toxicity with a true rate of >20%.
All toxicity was summarized in a tabular manner for all encountered
events. The MTD or the highest dose tested was to be expanded to 10
patients.
Results
Patient characteristics. Characteristics of the 25 patients
enrolled in this study are summarized in Table 1. The median
time on study was three cycles (12 weeks). Five patients
completed all 6 cycles of docetaxel and erlotinib, and three
patients continued erlotinib for 8, 10, and 12 cycles, respective-
ly. Four patients discontinued therapy before completing the
Table 1. Characteristics of 25 enrolled patients
Characteristic Number %













Non–small cell lung 4 16
Esophageal 4 16
Pancreatic 4 16
Transitional cell 3 12









1 regimen 7 28




Abbreviation: ECOG, Eastern Cooperative Oncology Group.
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first cycle: one patient due to DLT (grade 3 enterocolitis), two
patients due to bilirubin fluctuation due to Gilbert’s syndrome
and inability to dose per protocol, and one patient due to
dysphagia from an esophageal stricture due to disease
progression. Twenty-two patients are evaluable for safety and
21 patients are evaluable for efficacy and pharmacokinetics.
Toxicity. The MTD of docetaxel in combination with
erlotinib was not reached in this study. Treatment summary
and DLT are provided in Table 2. One of six patients at dose
level 25 mg/m2 experienced a DLT with grade 3 diarrhea,
nausea, and vomiting on cycle 1, day 10 and was hospitalized
on cycle 1, day 14. The last docetaxel dose was on cycle 1, day 8,
and the last erlotinib dose was on cycle 1, day 14. This patient
with metastatic bladder cancer and treated with two prior
chemotherapy regimens and pelvic radiotherapy was diagnosed
with grade 3 enterocolitis and with partial small bowel
obstruction and small amount of free air on abdominal
computed tomography scan. Diarrhea improved with diphe-
noxylate/atropine and i.v. fluids. A surgical evaluation consid-
ered that the patient had a sigmoid perforation possibly due to
metastatic tumor implants, but because of clinical improve-
ment, the patient declined surgical exploration. This DLT was
attributed to both docetaxel and erlotinib and the patient
discontinued the study on cycle 1, day 14. The patient
recovered without surgery and was discharged home in stable
condition 2 days after study discontinuation. One patient in the
25 mg/m2 docetaxel cohort was diagnosed with grade 2
interstitial pneumonitis on cycle 3, day 26, which responded
to treatment with steroids. The last docetaxel dose was on cycle
3, day 15, and the last erlotinib dose was on cycle 3, day 22.
The patient discontinued the study on cycle 3, day 26 but died
23 days later due to progressive metastatic pancreatic cancer.
The interstitial lung disease was attributed to the combination
of erlotinib and docetaxel.
No patients treated with 20 to 30 mg/m2 docetaxel required
dose reductions, but 6 of 10 patients in the 35 mg/m2 cohort
needed dose reductions to 30 mg/m2 beyond cycle 1 as follows:
on cycle 2, day 1, three patients due to grade 3 neutropenia
(including a patient dose reduced again on cycle 3, day 1 to
25 mg/m2 due to grade 2 infection) and one patient due to
grade 3 mucositis; on cycle 3, day 1, one patient dose reduced
due to grade 1 hyperbilirubinemia; and on cycle 4, day 1, one
patient dose reduced due to persistent grade 2 diarrhea and
abdominal cramping. In addition, one patient discontinued
docetaxel on cycle 5, day 15 due to grade 1 epiphora (eye
tearing; Table 2). One of three patients in the 30 mg/m2 cohort
received six cycles of docetaxel with no dose reductions, and
two patients had disease progression after two cycles. Among
six patients who required dose reductions from 35 to
30 mg/m2, four patients received only one additional cycle
due to disease progression, one patient (grade 3 diarrhea at
35 mg/m2) received three additional cycles of therapy, and one
patient (grade 1 hyperbilirubinemia at 35 mg/m2) received four
additional cycles at 30 mg/m2, respectively, with no recurrence
of prior toxicity. Thus, in the absence of disease progression,
cumulative dosing at 30 mg/m2 was tolerable, justifying this as
the recommended dose for phase II testing.
Erlotinib was dose reduced in two patients in the 25 mg/m2
cohort due to grade 2 conjunctivitis (cycle 3, day 15) and grade
2 mucositis (cycle 2, day 15), respectively.
Hematologic toxicity was uncommon, except for grade 3
neutropenia during the cycle 1 in 3 of 10 patients in the
35 mg/m2 dose level, which has not recurred after docetaxel
dose reduction in subsequent cycles, and one of the non-
evaluable patients (due to Gilbert’s) had grade 4 neutropenia
while off study (Table 3).
Nonhematologic drug-related adverse events are summarized
in Table 3. The most common toxicities were diarrhea, rash,
Table 2. Treatment summary, DLTs (N = 22 patients evaluable)
Docetaxel dose
level (mg/m2)





Drug 1st day DR DC Off study Reason for DR/DC
20 (n = 3) 4 (2-4) 4 (2-4) 0/3 D, E — C4D1 C4D8 gr 3 thrombocytopenia
25 (n = 6) 3 (1-6) 3 (1-6) 1/6 D, E — C1D15 C1D15 gr 3 enterocolitis
E C2D15 C4D15 gr 2 mucositis
E C3D15 C6D15 gr 2 conjunctivitis
E C3D26 gr 2 pneumonitis
30 (n = 3) 2 (2-6) 2 (2-6) 0/3 —
35 (n = 10) 3 (2-6) 3 (2-12) 0/10 D — C5D15 C12D28 gr 1 eye tearing
D — C6D15 C6D23 gr 3 neuropathy
D C2D1 C2D15 C3D1 gr 3 neutropenia
D C2D1 C2D15 C3D1 gr 3 neutropenia
D C2D1 C3D15 C3D15 gr 3 neutropenia
C3D1* C3D15 C3D15 gr 2 infection
D C4D1 C6D15 C9D1 gr 3 diarrhea
D C3D1 C6D15 C10D28 gr 1 hyperbilirubinemia
D C2D1 C3D1 C3D1 gr 3 mucositis
Abbreviations: AE, adverse event; D, docetaxel; E, erlotinib; DR, dose reductions; DC, discontinuation; gr, grade toxicity; C4D1, cycle 4, day 1;
C4D8, cycle 4, day 8; C1D15, cycle 1, day 15; C2D15, cycle 2, day 15; C4D15, cycle 4, day 15; C3D15, cycle 3, day 15; C6D15, cycle 6, day 15;
C3D26, cycle 3, day 26; C5D15, cycle 5, day 15; C12D28, cycle 12, day 28; C6D23, cycle 6, day 23; C2D1, cycle 2, day 1; C3D1, cycle 3, day 1;
C4D1, cycle 4, day 1; C9D1, cycle 9, day 1; C10D28, cycle 10, day 28.
*One patient had two docetaxel dose reductions.
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and mucositis, but most cases were grade 1 or 2. Grade 3/4
nonhematologic adverse events occurring in more than one
patient were diarrhea (three patients), mucositis (two patients),
and nausea, vomiting, dyspnea, and neuropathy (one patient
each).
Recommended phase II dose. We did not define the dose level
of weekly docetaxel in combination with erlotinib with excess
DLT during cycle 1 per protocol definition. However, because a
substantial proportion of patients required docetaxel dose
reduction to 30 mg/m2 for ongoing dosing beyond cycle 1, and
this dose proved tolerable with repetitive dosing, our recom-
mendation for phase II dosing will be 30 mg/m2 docetaxel
weekly for 3 of 4 weeks and 150 mg erlotinib daily.
Pharmacokinetics. Twenty-one patients had pharmaco-
kinetic studies completed. The mean docetaxel clearance was
61.7 L/h (range, 30.6-112.3), the mean volume of distribution
was 8.0 L (range, 3.8-13.1), and the area under the plasma
concentration-time curve (AUC) from time 0 to 24 h (AUC0-24)
was 0.986 Agh/mL (Table 4). A plot of plasma concentration-
time curves for docetaxel for each dose level is shown in
Fig. 1A. The mean erlotinib (OSI-774) clearance (FSD) was
8.16 F 4.05 L/h with AUC0-24 of 24.08 F 13.77 Agh/mL and
maximum plasma concentration (Cmax) of 1,381 F 692.8 ng/
mL. The OSI-420 had an AUC0-24 of 3.15 F 2.36 Agh/mL and
Cmax of 190.5 F 122 ng/mL (Table 5). A plot of average (FSD)
erlotinib and OSI-420 concentrations is shown in Fig. 1B.
Correlation of acneiform skin rash to plasma erlotinib
exposure. The incidence and severity of rash (grade 0/1 versus
grade z2) were analyzed in 21 patients and correlated with
erlotinib pharmacokinetics. We noted a significant correlation
between rash grade and the erlotinib plasma exposure.
Specifically, patients with acneiform rash that was grade z2
(n = 12) had a higher AUC0-24 (30.927 Agh/mL) than patients
with grade 0/1 rash (n = 9; AUC0-24, 14.959 Agh/mL; P =
0.003).
Antitumor activity. Twenty-one patients were evaluable for
tumor response according to Response Evaluation Criteria in
Solid Tumors criteria. Four patients (19%) obtained confirmed
partial responses to therapy. One patient with hepatocellular
carcinoma who previously underwent partial hepatectomy
relapsed 5 months later with lung metastases and an
a-fetoprotein level of 2,279. This patient obtained a complete
response after two cycles of therapy (35 mg/m2 docetaxel) and
is alive with no evidence of disease more than 36 months since
commencing protocol therapy (a-fetoprotein normalized at
3.4). Two patients with cholangiocarcinoma had tumor
response: one patient treated with 35 mg/m2 docetaxel showed
a partial response that lasted for 8 months and another patient
treated with 25 mg/m2 docetaxel had a minor response (20%
decrease in tumor) lasting 2 months; this patient was removed
from study due to biliary stent malfunction preventing redosing
per protocol due to bilirubin elevation. One patient with
prostate cancer with liver and soft tissue metastases treated with
35 mg/m2 docetaxel obtained a partial response for 8 months.
A patient with non–small cell lung cancer and prior history of
treated brain metastases in the 25 mg/m2 cohort had a partial
response of an isolated hilar mass, which lasted for 6 months.
This patient later received chest radiotherapy and has been with
no evidence of disease for more than 26 months. All responses
were documented after two cycles of therapy. Six patients (28%;
two non–small cell lung cancer, one cholangiocarcinoma, one
gastric, one bladder, and one colon) had stable disease lasting 2
to 6 months. Responding and stable disease patients received a
median of 6 cycles of docetaxel and erlotinib combination
therapy (range, 4-6 cycles of docetaxel and 4-12 cycles of
erlotinib).
Table 3. Summary of adverse events (National
Cancer Institute Common Terminology Criteria for












Grade 1 0 0 0 0
Grade 2 0 1 0 0
Grade 3 0 0 0 3
Grade 4 0 0 0 1
Thrombocytopenia
Grade 1 0 0 0 1
Grade 2 0 1 0 0
Grade 3 1 1 0 0
Grade 4 0 0 0 0
Anemia
Grade 1-4 0 0 0 0
Nonhematologic adverse events
Fatigue
Grade 1/2 1 1 0 6
Grade 3 0 0 0 0
Nausea
Grade 1/2 2 1 1 5
Grade 3 0 1 0 0
Vomiting
Grade 1/2 1 0 0 1
Grade 3 0 1 0 0
Diarrhea
Grade 1/2 3 4 3 8
Grade 3 0 1 0 2
Enterocolitis
Grade 1/2 0 0 0 0
Grade 3 0 1 0 0
Oral mucositis
Grade 1/2 1 2 2 8
Grade 3 0 0 0 2
Rash
Grade 1/2 3 4 3 10
Grade 3 0 0 0 0
Infection
Grade 1/2 0 0 0 2
Grade 3 0 0 0 0
Eye tearing
Grade 1/2 0 1 0 3
Grade 3 0 0 0 0
Interstitial lung disease
Grade 1/2 0 1 0 0
Grade 3 0 0 0 0
Dyspnea
Grade 1/2 0 1 0 3
Grade 3 0 1 0 0
Neuropathy
Grade 1/2 0 1 0 3
Grade 3 0 0 0 1
Nail changes
Grade 1/2 0 0 0 4
Grade 3 0 0 0 0
Cracked skin
Grade 1/2 0 1 0 4
Grade 3 0 0 0 0
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Discussion
Results of this phase I study show that the combination of
daily erlotinib and weekly docetaxel can be tolerated, but with
repetitive dosing at 35 mg/m2 of docetaxel, most patients
experienced drug-related toxicities, especially neutropenia,
diarrhea, and mucositis, prompting docetaxel dose reductions
to 30 mg/m2 beyond the first cycle (Table 2). All three patients
who developed grade 3 neutropenia had received chemother-
apy with one or more prior regimens, and two of these three
patients also had prior radiotherapy. Only one other patient in
this cohort was treated with prior chemotherapy and did not
require dose reductions for myelosuppression, suggesting
that prior treatment with chemotherapy may have been a
predisposing factor for myelosuppression from the docetaxel-
erlotinib combination. The one patient who required docetaxel
dose reduction for diarrhea with no associated myelosuppres-
sion on cycle 4, day 1 had prior pelvic radiotherapy and
hormonal therapy for prostate cancer. Patients treated with 30
mg/m2 tolerated repetitive dosing for up to six cycles, with no
major toxicity. Overall, the most common adverse events were
gastrointestinal and dermatologic and were seen across dose
levels, but more grade 3/4 toxicities occurred at 35 mg/m2
docetaxel dose level. Although rash was commonly seen and
could be attributed to erlotinib, no patient had grade 3 or 4
skin toxicity, and its incidence was not higher than expected
with single-agent erlotinib (12).
The pharmacokinetic variables of docetaxel on cycle 2, day 1
were similar to those reported for single-agent docetaxel given
every 3 weeks at doses of 60 to 115 mg/m2 (27, 28) or weekly at
35 mg/m2 (Table 4; ref. 29). Four patients treated with
35 mg/m2 docetaxel were dose reduced to 30 mg/m2 on cycle
2, day 1. Their pharmacokinetic variables were similar
compared with the patients who received full dose docetaxel
(clearance, 58.67 versus 68.11 L/h; volume of distribution, 3.4
versus 3.75 L/m2; and AUC0-24, 0.99 versus 1.00 Agh/mL).
Erlotinib pharmacokinetic variables indicate similar Cmax
[1,381 ng/mL (this study) versus 1,136-1,238 ng/mL (historical
controls)] and clearance [8.16 L/h (this study) versus 10.11 L/h
(controls)] as other phase I studies with single-agent erlotinib
(Table 5; refs. 30, 31). All patients achieved erlotinib
concentration values in excess of 500 ng/mL, which is the
concentration associated with antitumor activity in preclinical
models. Due to no appreciable difference from historical
controls, these data suggest no effect on the clearance of either
drug with the combination of docetaxel and erlotinib.
Although tumor evaluation was not the primary objective of
this study, five confirmed objective responses were seen










day 29 (current study)
1,539 F 397.5 1.037 F 0.39 30.56 F 9.33 61.7 (30.6-112.3)
Docetaxel (35 mg/m2),
day 1 (29)
1,850 F 730 1.32 F 0.42 29.1 F 10.2 NA
Abbreviations: Cl, clearance determined by dividing the dose by the AUC; NA, not available.
Fig. 1. A, plasma concentration-time profile for docetaxel at 20 mg/m2 (5), 25 mg/m2 (n), 30 mg/m2 (o), and 35 mg/m2 (.) on cycle 2, day1. B, plasma concentration-
time profile for erlotinib (OSI-774; .) and OSI-420 (o) on cycle 2, day1.
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(hepatocellular carcinoma, cholangiocarcinoma, non–small
cell lung cancer, and prostate cancer). Advanced-stage hepato-
cellular carcinoma and biliary malignancies have a dismal
prognosis, and neither chemotherapy nor biological therapies
prolong median survival beyond 1 year. One patient with
hepatocellular carcinoma obtained a complete response lasting
36+ months, and two patients with cholangiocarcinoma
obtained responses, one with partial response for 8 months.
The benefit of adding EGFR tyrosine kinase inhibitors to
chemotherapy was initially doubted based on two platinum
doublet trials with or without an EGFR tyrosine kinase
inhibitor, which yielded negative results in non–small cell
lung cancer (32–34). However, a small but meaningful benefit
was seen in some patients when gemcitabine was combined
with erlotinib in pancreatic cancer (13). The sequence-
dependent antiproliferative effects of cytotoxic drugs and EGFR
inhibitors may be important, as synergistic activity was seen
preclinically when chemotherapy was followed by treatment
with EGFR antagonists (35). Although not noticed in our and
other studies, another possibility for the discrepancy between
the preclinical and clinical data is that of a drug-drug
interaction resulting in decreased exposure to one or more of
the agents.
In conclusion, this study showed that weekly docetaxel can
be combined with daily erlotinib, but 35 mg/m2 docetaxel is
intolerable with repetitive dosing beyond the first cycle.
Although no MTD was reached in cycle 1 with 35 mg/m2
docetaxel, the recommended phase II dose of weekly docetaxel
is 30 mg/m2 when combined with 150 mg of daily erlotinib.
Combined dosing of docetaxel and erlotinib did not seem to
alter the pharmacokinetics of either drug. The antitumor
activity of this regimen provides the rationale for further testing
in phase II studies of various solid tumors, including
hepatobiliary malignancies.
Table 5. Pharmacokinetic variables for erlotinib (OSI-774) and OSI-420 on day 29 (cycle 2, day 1) versus
day 1 single-agent erlotinib historical controls
Cmax (ng/mL), mean F SD AUC0-24 (Mgh/mL), mean F SD Cl/F (L/h), mean F SD
OSI-774 (150 mg/d), day 29 (current study) 1,381 F 692.8 24.08 F 13.77 8.16 F 4.05
OSI-774 (150 mg/d), day 1 arm B (31) 1,136 F 865 16.51 F 11.02 10.11 F 12.51
OSI-774 (150 mg/d), day 1 arm C (31) 1,238 F 598 18.61 F 5.99 NA
OSI-420, day 29 (current study) 190.5 F 122 3.15 F 2.36 NA
OSI-420, day 1 (31) 85 F 38 1.69 F 1.42 NA
Abbreviation: Cl/F, oral clearance determined by dividing the dose by the AUC.
Cancer Therapy: Clinical
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